Aytu BioPharma, Inc. reported a decline in financial performance for the second quarter of fiscal 2026, with net revenue of $15.2 million for the three months ended December 31, 2025, down from $16.2 million in the same period last year. For the six months, revenue decreased to $29.1 million from $32.8 million year-over-year. The company attributed this decline primarily to a strategic shift in marketing focus towards its newly launched product, EXXUA, which is aimed at treating major depressive disorder (MDD). The ADHD and Pediatric product portfolios saw reduced marketing emphasis, contributing to lower sales in those areas.
The company's gross profit also fell, totaling $9.6 million for the quarter, compared to $10.8 million a year earlier, reflecting a gross profit margin decrease from 66% to 63%. This decline was influenced by a $0.8 million inventory write-down related to a transition from branded to generic products. Operating expenses decreased to $11.6 million from $12.5 million, driven by reduced restructuring costs and a suspension of research and development activities. However, the company still reported a net loss of $10.6 million for the quarter, compared to a net income of $0.8 million in the prior year.
Aytu BioPharma has made significant strategic moves, including the successful launch of EXXUA, which is expected to be a key growth driver. The company entered into a Commercialization Agreement with Fabre-Kramer Holdings, Inc. for EXXUA, which is a first-in-class treatment for MDD. The company is also focusing on international collaborations for its ADHD products, with agreements in place for commercialization in Israel and Canada. These strategic initiatives are part of Aytu's broader goal to enhance its market presence and improve financial performance.
Operationally, Aytu's total assets decreased to $122.0 million as of December 31, 2025, down from $124.2 million at the end of the previous fiscal period. The company reported a cash position of $30.0 million, slightly down from $30.9 million. The total liabilities increased to $107.8 million, primarily due to higher accounts payable and accrued liabilities. The company’s employee headcount remained stable, reflecting its focus on maintaining operational efficiency amid restructuring efforts.
Looking ahead, Aytu BioPharma aims to accelerate the growth of its commercial business and achieve positive operating cash flows. The company has suspended active development of clinical programs to concentrate on its commercial operations and is evaluating potential strategic transactions to enhance shareholder value. Despite the challenges faced in the current fiscal period, Aytu remains optimistic about the future potential of EXXUA and its other product lines as it navigates a competitive and evolving market landscape.
About AYTU BIOPHARMA, INC
Aytu BioPharma, Inc. is a pharmaceutical company specializing in innovative treatments for central nervous system disorders, primarily major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Its core products include EXXUA, a novel selective serotonin 5HT1a receptor agonist for MDD, and extended-release orally disintegrating tablets Adzenys and Cotempla for ADHD. The company also offers pediatric allergy and fluoride supplement products, marketing primarily in the U.S. through third-party wholesalers and an internal sales force.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.